Niagen Bioscience, Inc. — Director's Dealing 2026

Feb 24, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Niagen Bioscience, Inc. (NAGE)
CIK: 0001386570
Period of Report: 2026-02-19

Reporting Person: Fried Robert N (Director, Chief Executive Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2026-02-19	Employee Stock Options (right to buy)	$4.94	A	503937	Acquired	2036-02-18	Common Stock (503937)	Direct

Footnotes

F1: One-fourth of the shares subject to the option shall vest on each anniversary of the grant date.